Abstract
Current pharmacological treatments for eating disorders and obesity are of limited value and thus the identification of novel targets is highly needed to enhance the development of more effective drugs. Among the bottlenecks limiting the introduction of new medicines is the reported heterogeneity of these diseases, which makes it difficult to find drugs with broad activity and the lack of animal models with translational validity, especially in the case of anorexia nervosa. Some kinds of obesity and eating disorders can be classified within the pathologies affecting the brain reward system together with drug addiction and others, and therefore specific treatments in these cases can be directed to restore normal function in brain reward pathways. Target identification in this field can greatly benefit from the combined application of genomic/proteomic techniques and robust animal models of reward deficits.
Keywords: Obesity, eating disorders, reward deficit, addiction
Current Pharmaceutical Design
Title: Identification of New Drug Targets and Biomarkers Related to Obesity and Eating Disorders: an Approach Based on Reward Deficit and Addiction
Volume: 17 Issue: 5
Author(s): Luis F Alguacil, Elisabet Salas and Carmen Gonzalez-Martin
Affiliation:
Keywords: Obesity, eating disorders, reward deficit, addiction
Abstract: Current pharmacological treatments for eating disorders and obesity are of limited value and thus the identification of novel targets is highly needed to enhance the development of more effective drugs. Among the bottlenecks limiting the introduction of new medicines is the reported heterogeneity of these diseases, which makes it difficult to find drugs with broad activity and the lack of animal models with translational validity, especially in the case of anorexia nervosa. Some kinds of obesity and eating disorders can be classified within the pathologies affecting the brain reward system together with drug addiction and others, and therefore specific treatments in these cases can be directed to restore normal function in brain reward pathways. Target identification in this field can greatly benefit from the combined application of genomic/proteomic techniques and robust animal models of reward deficits.
Export Options
About this article
Cite this article as:
F Alguacil Luis, Salas Elisabet and Gonzalez-Martin Carmen, Identification of New Drug Targets and Biomarkers Related to Obesity and Eating Disorders: an Approach Based on Reward Deficit and Addiction, Current Pharmaceutical Design 2011; 17 (5) . https://dx.doi.org/10.2174/138161211795164158
DOI https://dx.doi.org/10.2174/138161211795164158 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
ABAD: A Potential Therapeutic Target for Aβ-Induced Mitochondrial Dysfunction in Alzheimers Disease
Mini-Reviews in Medicinal Chemistry Genetically-mediated Grey and White Matter Alteration in Normal Elderly Individuals with the CLU-C Allele Gene
Current Alzheimer Research Phytocompounds as Potential Agents to Treat Obesity-Cardiovascular Ailments
Cardiovascular & Hematological Agents in Medicinal Chemistry Designing, Optimisation & Characterization of Sustained Release Matrix Pellets Prepared by Extrusion Spheronization Containing Mixture of Proteolytic Enzymes
Current Drug Delivery Lipid Biomarkers in Alzheimer's Disease
Current Alzheimer Research Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: A Review
Current Drug Therapy AMPK as a Potential Anticancer Target - Friend or Foe?
Current Pharmaceutical Design Effectiveness of Hsp90 Inhibitors as Anti-Cancer Drugs
Mini-Reviews in Medicinal Chemistry Immunotherapy for Prostate Cancer
Current Pharmaceutical Design The Experience of Combining Agents, Specially Triptans and Non Steroidal Anti-Inflammatory Drugs, for the Acute Treatment of Migraine - A Review
Recent Patents on CNS Drug Discovery (Discontinued) KMC, Concepts, Definitions and Praxis: What Elements are Applicable in What Settings in Which Local Circumstances?
Current Women`s Health Reviews The Cell Cycle Molecules Behind Neurodegeneration in Alzheimers Disease: Perspectives for Drug Development
Current Medicinal Chemistry Cognitive Flexibility as a Key Factor in the Conceptualization and Treatment of PTSD
Current Psychiatry Reviews Preclinical Data Supporting/Refuting the Use of Hypericum perforatum in the Treatment of Depression
CNS & Neurological Disorders - Drug Targets Metabotropic Glutamate Receptors in the Control of Mood Disorders
CNS & Neurological Disorders - Drug Targets Magnetic Resonance-Based Metabolomics for Understanding Neurological Disorders: Current Status and Statistical Considerations
Current Metabolomics 5-Benzylidene-3,4-dihalo-furan-2-one derivatives inhibit human leukemia cancer cells through suppression of NF-κB and GSK-3β
Anti-Cancer Agents in Medicinal Chemistry RNAi of cat-2, a Putative Tyrosine Hydroxylase, Increases Alpha Synuclein Aggregation and Associated Effects in Transgenic C. elegans
CNS & Neurological Disorders - Drug Targets Hyperfibrinogenemia is Significantly Associated with an Increased Risk of In-hospital Mortality in Acute Ischemic Stroke Patients
Current Neurovascular Research Computer-Aided Discovery in Antimicrobial Research: In Silico Model for Virtual Screening of Potent and Safe Anti-Pseudomonas Agents
Combinatorial Chemistry & High Throughput Screening